Actinium Pharmaceuticals Inc (ATNM) Börsenkurse

Actinium develops Antibody Radiation Conjugates ('ARCs') and other targeted radiotherapies intended to meaningfully improve outcomes for people who have failed existing oncology therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and re... Actinium develops Antibody Radiation Conjugates ('ARCs') and other targeted radiotherapies intended to meaningfully improve outcomes for people who have failed existing oncology therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia ('r/r AML'), which Actinium plans to advance with a potential strategic partner in the U.S. following completion of FDA interactions. The company continues to advance its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, Actinium is engaged with the National Cancer Institute ('NCI') under the Cooperative Research and Development Agreement ('CRADA') for development of Actimab-A in AML and other myeloid malignancies. Mehr anzeigen